Francesco D'Amico, MD, PhD, FEBS
Cards
About
Research
Publications
2024
Full-left/Full-right Liver Splitting With Middle Hepatic Vein and Caval Partition During Dual Hypothermic Oxygenated Machine Perfusion
Cillo U, Lauterio A, Furlanetto A, Canitano N, Polacco M, Buscemi V, De Carlis R, Boetto R, D’Amico F, Bassi D, De Carlis L, Gringeri E. Full-left/Full-right Liver Splitting With Middle Hepatic Vein and Caval Partition During Dual Hypothermic Oxygenated Machine Perfusion. Transplantation 2024, 108: 1417-1421. PMID: 38755751, DOI: 10.1097/tp.0000000000005039.Peer-Reviewed Original ResearchMiddle hepatic veinHypothermic oxygenated machine perfusionOxygenated machine perfusionHepatic veinVena cavaMachine perfusionEffects of ischemia-reperfusion injuryLiver splittingDual hypothermic oxygenated machine perfusionIschemia-reperfusion injuryProlonged cold ischemiaSplit liver transplantationEx situ splittingPediatric patientsVenous reconstructionParenchymal transectionAdult patientsLiver transplantationHepatocellular carcinomaVenous congestionRight graftCold ischemiaVenous outflowProlonged ischemiaImprove outcomesRecurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
Berardi G, Cucchetti A, Sposito C, Ratti F, Nebbia M, D’Souza D, Pascual F, Dogeas E, Tohme S, Vitale A, D’Amico F, Alessandris R, Panetta V, Simonelli I, Colasanti M, Russolillo N, Moro A, Fiorentini G, Serenari M, Rotellar F, Zimitti G, Famularo S, Ivanics T, Donando F, Hoffman D, Onkendi E, Essaji Y, Giuliani T, Ben S, Caula C, Rompianesi G, Chopra A, Abu Hilal M, Sapisochin G, Torzilli G, Corvera C, Alseidi A, Helton S, Troisi R, Simo K, Conrad C, Cescon M, Cleary S, Kwon D, Ferrero A, Ettorre G, Cillo U, Geller D, Cherqui D, Serrano P, Ferrone C, Aldrighetti L, Kingham T, Mazzaferro V. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome. JHEP Reports 2024, 6: 101075. PMID: 38961853, PMCID: PMC11220535, DOI: 10.1016/j.jhepr.2024.101075.Peer-Reviewed Original ResearchLong-term outcomes of liver resectionRecurrence-free survivalTime of recurrenceCancer-specific survivalTumor-related factorsDevelopment of hepatocellular carcinomaHepatocellular carcinomaMetabolic syndromeLong-term survivalRisk factorsOverall survivalImpact survivalResection of hepatocellular carcinomaOutcomes of liver resectionCurative intent approachPost-recurrence survivalPredictors of recurrenceHazard of recurrenceTreatment of recurrenceRisk of recurrenceTumor-related deathLong-term outcomesDesigning future trialsAssociated with deathMedian OSLIVING DONOR LIVER DONATION IN THE ONCOLOGICAL FIELD: WHAT’S NEW
Gringeri E, Furlanetto A, Lanari J, Marchini A, Dolcet A, Bassi D, Boetto R, D’Amico F, Bertacco A, Perin L, Nieddu E, Ballo M, Rosso E, Nardi C, Canitano N, Cillo U. LIVING DONOR LIVER DONATION IN THE ONCOLOGICAL FIELD: WHAT’S NEW. European Journal Of Transplantation 2024, 2: 22-28. DOI: 10.57603/ejt-434.Peer-Reviewed Original ResearchWhat Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis?
Vitale A, Angelico R, Sensi B, Lai Q, Kauffmann E, Scalera I, Serenari M, Ginesini M, Romano P, Furlanetto A, D’Amico F. What Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis? Cancers 2024, 16: 966. PMID: 38473327, PMCID: PMC10930835, DOI: 10.3390/cancers16050966.Peer-Reviewed Original ResearchMinimally invasive liver surgeryOpen surgeryLiver surgerySignificant cardiovascular riskTrans-arterial approachResection outcomesLaparoscopic ablationResected casesLiver transplantationTreated patientsHepatocellular carcinomaEfficacious therapyCardiovascular riskSurgeryPatientsNarrative reviewTreatment hierarchyCurative techniqueHCCResectionCarcinomaCirrhosisTransplantationTherapyEx situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy
Nieddu E, Billato I, Peluso C, Furlanetto A, Lazzari S, D'Amico F, Cillo U, Gringeri E. Ex situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy. Digestive And Liver Disease 2024, 56: s42. DOI: 10.1016/j.dld.2024.01.067.Peer-Reviewed Original ResearchProgression-free survivalCA19-9 levelsEx situ liver resectionOverall survivalIntrahepatic cholangiocarcinomaEx situ surgeryStage of diseasePerformance statusSystemic chemotherapySurgical resectionLiver resectionLiver functionHigh-volume hepatobiliary centersLower stage of diseaseMedian progression-free survivalTreated with surgical resectionEvaluate long-term outcomesSurvival analysisEx situ resectionNon-parametric log-rank testTreated with chemotherapyLog-rank testLiver function testsCox regression analysisLong-term outcomesLiver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
Romano P, Busti M, Billato I, D’Amico F, Marchegiani G, Pelizzaro F, Vitale A, Cillo U. Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis. BJS Open 2024, 8: zrad158. PMID: 38323881, PMCID: PMC10848305, DOI: 10.1093/bjsopen/zrad158.Peer-Reviewed Original ResearchConceptsBarcelona Clinic Liver CancerTrans-arterial chemoembolizationDisease-free survivalBarcelona Clinic Liver Cancer-A patientsBenefits of LRLiver resectionRadiofrequency ablationHepatocellular carcinomaOS benefitOverall survivalA patientsBarcelona Clinic Liver Cancer ABarcelona Clinic Liver Cancer stageDisease-free survival benefitRisk ratioOutcomes of LRMeta-analysisComparative cohort studyCase-control studyChina Biological Medicine DatabaseHCC patientsCohort studyPrimary outcomeNewcastle-OttawaQuality of studiesAblation and resection in the surgical treatment of liver metastases from colorectal cancer: analysis of procedure-related recurrence patterns
D'Amico F, Alessandris R, Della Libera M, Castigliego R, Bassi D, Marchini A, Lanari J, Gringeri E, Cillo U. Ablation and resection in the surgical treatment of liver metastases from colorectal cancer: analysis of procedure-related recurrence patterns. Hepato Pancreato Biliary 2024, 26: s181. DOI: 10.1016/j.hpb.2024.03.338.Peer-Reviewed Original ResearchThe crucial role of abdominal procurement surgery as a prerequisite for pancreatoduodenectomy: an overview
Bassi D, Caregari S, D'Amico F, Marchegiani G, Cillo U. The crucial role of abdominal procurement surgery as a prerequisite for pancreatoduodenectomy: an overview. Hepato Pancreato Biliary 2024, 26: s501. DOI: 10.1016/j.hpb.2024.03.1059.Peer-Reviewed Original ResearchUpfront surgery vs. upfront chemotherapy for multiple, centimetric, resectable colorectal liver metastasis: a single institution study
D'Amico F, Alessandris R, Castigliego R, Della Libera M, Bassi D, Marchini A, Lanari J, Gringeri E, Cillo U. Upfront surgery vs. upfront chemotherapy for multiple, centimetric, resectable colorectal liver metastasis: a single institution study. Hepato Pancreato Biliary 2024, 26: s180-s181. DOI: 10.1016/j.hpb.2024.03.337.Peer-Reviewed Original Research
2023
Anatomic Versus Nonanatomic Resection
Cillo U, Marchini A, D’Amico F, Gringeri E. Anatomic Versus Nonanatomic Resection. 2023, 55-58. DOI: 10.1007/978-3-031-35295-9_6.Peer-Reviewed Original ResearchTarget lesionsNonanatomical liver resectionColorectal liver metastasesInvasive liver surgeryViable liver tissueLiver pedicleNonanatomic resectionAnatomical resectionOncological outcomesLiver metastasesLiver resectionNonanatomical resectionLiver surgeryResectionLiver tissueAnatomical regionsLesionsSurgeryMetastasisHCCPedicleParenchyma